Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 11, 2017, Pages 3079-3084

  Schaumburg, Frieder ^a   Bletz, Stefan ^a   Mellmann, Alexander ^a   Becker, Karsten ^a   Idelevich, Evgeny A ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; CYTOSKELETON PROTEIN; MBL PROTEIN, BACILLUS SUBTILIS; PENICILLANIC ACID;

ACCURACY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; DISK DIFFUSION; GENETIC RESISTANCE; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DEVICES; DRUG EFFECT; GENETICS; GERMANY; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTILOCUS SEQUENCE TYPING; PROCEDURES;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CEPHALOSPORINS; CYTOSKELETAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GERMANY; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85041036384     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx253     Document Type: Article

References (22)

1. Gentile I, Maraolo AE, Borgia G. What is the role of the new b-lactam/b-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert Rev Anti Infect Ther 2016; 14: 875-8
2. [Hygiene measures for infection or colonization with multidrug-resistant gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 1311-54
3. Magiorakos AP, SrinivasanA, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81
4. International Organization for Standardization (ISO). ReferenceMethod for Testing the In Vitro Activity of Antimicrobial Agents Against Rapidly Growing Aerobic Bacteria Involved in Infectious Diseases: 20776-1. Part 1. Geneva, Switzerland: ISO, 2006
5. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Tenth Edition: Approved Standard M07-A10. CLSI, Wayne, PA, USA, 2015
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-seventh Informational SupplementM100-S27. CLSI, Wayne, PA, USA, 2017
7. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 7. 0. 2017. www. eucast. org
8. Pitout JDD, Gregson DB, Poirel L et al. Detection of Pseudomonas aeruginosa producingmetallo-b-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43: 3129-35
9. Pfennigwerth N, Lange F, Belmar Campos C et al. Genetic and biochemical characterization of HMB-1, a novel subclass B1 metallo-b-lactamase found in a Pseudomonas aeruginosa clinical isolate. J Antimicrob Chemother 2017; 72: 1068-73
10. Yong D, Toleman MA, Bell J et al. Genetic and biochemical characterization of an acquired subgroup B3 metallo-b-lactamase gene, blaAIM-1, and its unique genetic context in Pseudomonas aeruginosa from Australia. Antimicrob Agents Chemother 2012; 56: 6154-9
11. Pollini S, Maradei S, Pecile P et al. FIM-1, a new acquiredmetallo-b-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob Agents Chemother 2013; 57: 410-6
12. LivermoreDM, Mushtaq S, MeunierD et al. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother 2017; 72: 2278-89
13. Sekiguchi J, Morita K, Kitao T et al. KHM-1, a novel plasmid-mediatedmetallo-b-lactamase from a Citrobacter freundii clinical isolate. Antimicrob Agents Chemother 2008; 52: 4194-7
14. Rossolini GM, Condemi MA, Pantanella F et al. Metallo-b-lactamase producers in environmental microbiota: new molecular class B enzyme in Janthinobacterium lividum. Antimicrob Agents Chemother 2001; 45: 837-44
15. Mellmann A, Bletz S, Böking T et al. Real-time genome sequencing of resistant bacteria provides precision infection control in an institutional setting. J ClinMicrobiol 2016; 54: 2874-81
16. Sader HS, Farrell DJ, Castanheira M et al. Antimicrobial activity of ceftolozane/ tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014; 69: 2713-22
17. Castanheira M, Mills JC, Farrell DJ et al. Mutation-driven b-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U. S. hospitals. Antimicrob Agents Chemother 2014; 58: 6844-50
18. Skalweit MJ. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Drug Des Devel Ther 2015; 9: 2919-25
19. Oliver A, Mulet X, Löpez-Causapé C et al. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Update 2015; 21-22: 41-59
20. Flynt LK, Veve MP, Samuel LP et al. Comparison of Etest to broth microdilution for testing of susceptibility of Pseudomonas aeruginosa to ceftolozanetazobactam. J ClinMicrobiol 2017; 55: 334-5
21. Idelevich EA, Büsing M, Mischnik A et al. False non-susceptible results of tigecycline susceptibility testing against Enterobacteriaceae by an automated system: amulticentre study. JMedMicrobiol 2016; 65: 877-81
22. US Department of Health and Human Services. Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems. Rockville, MD, USA: USFDA, 2009